Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-gorelated gene mutant

Heart Rhythm

Volumn 9, Issue 2, 2012, Pages 265-272

  Soucek, Radim ^a   Thomas, Dierk ^a   Kelemen, Kamilla ^a   Bikou, Olympia ^a   Seyler, Claudia ^a   Voss, Frederik ^a   Becker, Rdiger ^a   Koenen, Michael ^b   Katus, Hugo A ^a   Bauer, Alexander ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MAX PLANCK INSTITUTE FOR MEDICAL RESEARCH   (Germany)

Author keywords

Atrial fibrillation; Gene therapy; HERG; Ion channel; Rhythm control

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; POTASSIUM CHANNEL HERG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL HEART PACEMAKER; CONTROLLED STUDY; DISEASE CONTROL; ELECTROPORATION; FEMALE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE MUTATION; GENE REPRESSION; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART REPOLARIZATION; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; SWINE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GREEN FLUORESCENT PROTEINS; HEART ATRIA; MUTATION; SUS SCROFA;

EID: 84856213683     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2011.09.008     Document Type: Article

References (29)

1. W.B. Kannel, R.D. Abbott, D.D. Savage Epidemiologic features of chronic atrial fibrillation: the Framingham study N Engl J Med 306 1982 1018 1022
2. D.M. Lloyd-Jones, T.J. Wang, E.P. Leip Lifetime risk for development of atrial fibrillation: the Framingham Heart Study Circulation 110 2004 1042 1046
3. W.H. Maisel, L.W. Stevenson Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy Am J Cardiol 91 Suppl 1 2003 2 8
4. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, H. Silbershatz, W.B. Kannel, D. Levy Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 1998 946 952
5. D. Dobrev, S. Nattel New antiarrhythmic drugs for treatment of atrial fibrillation Lancet 375 2010 1212 1223
6. P. Attuel, R. Childers, B. Cauchemez, J. Poveda, J. Mugica, P. Coumel Failure in the rate adaptation of the atrial refractory period: its relationship to vulnerability Int J Cardiol 2 1982 179 197
7. M.C.E. Wijffels, C.J.H. Kirchhof, R. Dorland, M.A. Allessie Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats Circulation 92 1995 1954 1968
8. J.K. Donahue, A.W. Heldman, H. Fraser Focal modification of electrical conduction in the heart by viral gene transfer Nat Med 6 2000 1395 1398
9. A. Bauer, A.D. McDonald, K. Nasir Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation Circulation 110 2004 3115 3120
10. K. Kikuchi, A.D. McDonald, T. Sasano, J.K. Donahue Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer Circulation 111 2005 264 270
11. G. Amit, K. Kikuchi, I.D. Greener, L. Yang, V. Novack, J.K. Donahue Selective molecular potassium channel blockade prevents atrial fibrillation Circulation 121 2010 2263 2270
12. K. Petrecca, R. Atanasiu, A. Akhavan N-linked glycosylation sites determine HERG channel surface membrane expression J Physiol 515 1999 41 48
13. S. Claassen, S. Schwarzer, B.J. Znkler Electrophysiological and fluorescence microscopy studies with HERG channel/EGFP fusion proteins J Membr Biol 222 2008 31 41
14. L. Hou, M. Deo, P. Furspan A major role for HERG in determining frequency of reentry in neonatal rat ventricular myocyte monolayer Circ Res 107 2010 1503 1511
15. M.C. Sanguinetti, M.E. Curran, P.S. Spector, M.T. Keating Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia Proc Natl Acad Sci U S A 93 1996 2208 2212
16. P. Babij, G.R. Askew, B. Nieuwenhuijsen Inhibition of cardiac delayed rectifier K+ current by overexpression of the long-QT syndrome HERG G628S mutation in transgenic mice Circ Res 83 1998 668 678
17. Z. Zhou, Q. Gong, M.L. Epstein, C.T. January HERG channel dysfunction in human long QT syndrome: intracellular transport and functional defects J Biol Chem 273 1998 21061 21066
18. E. Ficker, A.T. Dennis, L. Wang, A.M. Brown Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel hERG Circ Res 92 2003 e87 e100
19. M. Brunner, X. Peng, G. Xin Liu, G. Koren Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome J Clin Invest 118 2008 2246 2259
20. J. Zehelein, W. Zhang, M. Koenen, H.A. Katus Molecular cloning and expression of cERG, the ether go-go-related gene from canine myocardium Pflugers Arch 442 2001 188 191
21. J. Gierten, E. Ficker, R. Bloehs Regulation of two-pore-domain K2P potassium leak channels by the tyrosine kinase inhibitor genistein Br J Pharmacol 154 2008 1680 1690
22. M.R. Franz, D. Burkhoff, H. Spurgeon, M.L. Weisfeldt, E.G. Lakatta In vitro validation of a new cardiac catheter technique for recording monophasic action potentials Eur Heart J 7 1986 34 41
23. N.B. Schiller, P.M. Shah, M. Crawford Recommendations for quantitation of the left ventricle by two-dimensional echocardiography J Am Soc Echocardiogr 2 1989 358 367
24. J. Gehl Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research Acta Physiol Scand 177 2003 437 447
25. L.M. Mir, M.F. Bureau, J. Gehl High-efficiency gene transfer into skeletal muscle mediated by electric pulses Proc Natl Acad Sci U S A 96 1999 4262 4267
26. S. Floyd, P.R. Clemens, M.R. Ontell, S. Kochanek, J. Huard Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles Gene Ther 1 1998 19 30
27. A.R. Misier, T. Opthof, N.M. van Hemel Increased dispersion of "refractoriness" in patients with idiopathic paroxysmal atrial fibrillation J Am Coll Cardiol 19 1992 1531 1535
28. S.H. Hohnloser Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management Am J Cardiol 80 1997 82G 89G
29. Y. Blaauw, U. Schotten, A. van Hunnik Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat Cardiovasc Res 75 2007 89 98